Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of NPC-22 for Sialorrhea in ALS
jRCT2031210612Phase 2Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypersalivation and amyotrophic lateral sclerosis (ALS) comparing NPC-22 transdermal tape with Placebo transdermal tape (2 arms). Primary endpoint: Safety endpoints. Started Mar 2022; status: completed.
02
Drugs
scopolamine
03
Conditions
hypersalivationamyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2031210612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210612.